Courtney Flaherty

The FDA granted a fast track designation to HC-7366 for adults with relapsed or refractory acute myeloid leukemia.

P-BCMA-ALLO1 elicited high response rates and a manageable safety profile in heavily pretreated, relapsed/refractory multiple myeloma.

Presurgical durvalumab plus chemotherapy, followed by adjuvant durvalumab, led to improved survival in patients with cisplatin-eligible muscle-invasive bladder cancer (MIBC).

GC012F, a BCMA/CD19–targeted CAR T-cell therapy, safely produced favorable outcomes in patients with newly diagnosed multiple myeloma after induction therapy.

Ozuriftamab vedotin, an ROR2-targeted antibody drug conjugate, received fast track designation from the FDA for recurrent or metastatic head and neck squamous cell carcinoma.

Perioperative pembrolizumab plus chemotherapy improves overall survival in patients with resectable gastric cancer.

Adding brentuximab vedotin to lenalidomide/rituximab results in a stronger overall survival benefit compared with lenalidomide/rituximab alone in relapsed/refractory diffuse large B-cell lymphoma.

The FDA granted the investigational menin-MLL inhibitor DSP-5336 fast track designation for KMT2A-rearranged/NPM1-mutant acute myeloid leukemia.

Ciltacabtagene autoleucel demonstrated a statistically significant improvement in overall survival for patients with relapsed/refractory multiple myeloma refractory to lenalidomide.

Compared with placebo, first-line rucaparib maintenance therapy maintained a PFS benefit at 4 years in newly diagnosed advanced ovarian cancer.

Six-year administration of imatinib maintenance therapy—compared with the standard 3 years—improved disease-free survival in gastrointestinal stromal tumors.

Compared with physician’s choice of treatment, trastuzumab deruxtecan exhibited superior long-term survival and response rates in patients with HER2-positive breast cancer.

Durvalumab monotherapy as consolidation therapy in limited-stage small cell lung cancer produced a clinical benefit in patients from the phase 3 ADRIATIC trial.

Patients with head and neck squamous cell carcinoma treated with atezolizumab after definitive local therapy did not see improvements in survival outcomes.

Superior 3-year survival outcomes were observed with durvalumab plus chemotherapy compared with chemotherapy alone in patients with advanced biliary tract cancer.

The FDA granted LSTA1 rare pediatric disease designation for the treatment of osteosarcoma.

First-line treatment with osimertinib and chemotherapy significantly improved survival outcomes after disease progression in EGFR-mutated NSCLC.

Patients with advanced hepatocellular carcinoma treated with nivolumab plus ipilimumab had an improvement in overall survival compared with standard-of-care TKIs.

A treatment for NTRK-positive locally advanced or metastatic solid tumors, repotrectinib, is currently under priority review by the FDA and may address a high unmet medical need.

The FDA granted an orphan drug designation to soquelitinib for potential use in T-cell lymphoma.

Patients with BRCA-, ATM- and CDK12-mutated mCRPC treated with frontline olaparib plus abiraterone acetate experienced delays in disease progression and improved outcomes.

Researchers determined that the phase 3 EVOKE-01 trial failed to meet its primary end point of significantly improved OS with sacituzumab govitecan in patients with pretreated non-small cell lung cancer compared with docetaxel.

A fast track designation has been granted by the FDA to the novel BTK degrader, NX-5948, for adults with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma who were treated with at least two lines of therapy, including a BTK inhibitor and a BCL2 inhibitor.

A survival advantage via treatment with lenvatinib plus pembrolizumab was not seen when compared with docetaxel for advanced-stage non–small cell lung cancer whose disease progressed after previous exposure to a PD-L1 inhibitor and platinum-based chemotherapy.

High disease burden may be associated with more bridging therapy use and contribute to worse outcomes, according to investigators.

Olaparib did not significantly improve overall survival compared with chemotherapy in recurrent, platinum-sensitive ovarian cancer.

An analysis of 3 randomized trials showed that acalabrutinib was associated with approximately half the number of cardiac toxicities than with comparator treatments.

Immuno-oncology regimens were linked with improved long-term survival among patients with hepatocellular carcinoma.

Patients with EGFR-mutated non–small cell lung cancer and MET positivity may derive greater benefit from amivantamab plus lazertinib than patients who are MET-negative.

Glofitamab monotherapy led to a 63.6% overall response rate in heavily pretreated patients with Richter syndrome.